Ocata Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

OCAT 6.20 -0.18 (-2.82%)
price chart
Advanced Cell Technology changes its name to Ocata
Ocata has no products on the market and has piled up millions of dollars in losses since its formation. Under the President and Chief Executive Paul K. Wotton, the company has been shoring up financing to support its research, settling lawsuits over ...
Related articles »  
Advanced Cell Technology Changes Name to Ocata Therapeutics
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc., (OTCBB: OCAT) today announced the change of its company name to Ocata Therapeutics, Inc., effective immediately. The change, which has been approved by the Company's ...
Related articles »  
Advanced Cell Technology Annual Meeting Announcement: A Harbinger Of ...
Advanced Cell Technology (ACTC) has scheduled its annual meeting for 9 AM on November 12th. The most interesting points on the agenda are a name change for the company to Ocata Therapeutics, and a proposal to increase the number of authorized ...
Related articles »  
Advanced Cell Technology's Turnaround Has Near-Term Catalysts (ACTC)
When Paul Wotton decided to leave a secure high paying CEO position at Antares Pharma to come aboard a financially strapped company with a history of bad financing decisions it was a turning point at ACT (soon to be known as Ocata Therapeutics).
Hot Stock's Alert - Magnum Hunter Resources (MHR), Ocata Therapeutics Inc ...
Ocata Therapeutics Inc (OTCMKTS:OCAT), a biotechnology company, develops and commercializes human pluripotent stem cell technology in the field of regenerative medicine in the United States.
Update: Advanced Cell Technology Reverse Split (ACTC)
Advanced Cell Technology (ACTC) has completed a 100 for 1 reverse split effective today, which is a precursor to the company's stated plans to up-list to Nasdaq. This is listed as the last of the 7 steps for rebuilding shareholder value and trust given ...
Related articles »  
Update: Advanced Cell Technology Interim Results And Shelf Offerings (ACTC)
As I said there, the particular journal that the results are published in will give the most immediate clue as to the company's prospects for the immediate future, so let's begin there. The Lancet is a very well respected medical journal, with an ...
Related articles »  
Advanced Cell Technology Has Groundbreaking Results (ACTC)
Last night, we were delivered incredible news from Advanced Cell Technology (ACTC) about two trials that they currently have under way in the US for age-related macular degeneration, the most common cause of vision loss in people over age 60, and ...
Related articles »  
Advanced Cell Technology: Time To Buy The Rumor (Again) (ACTC)
Part of the appreciation in the stock price could be the fact the company re-upped its stock purchase agreement with Lincoln Park Capital for an additional $30 million on July 3rd.
Related articles »  
Advanced Cell Technology: All Systems Go (ACTC)
What is extremely important to note, and I think is often left out of the conversation by disgruntled shareholders, is that even if the company was to fully dilute the authorized shares and once again max out the availability, it would have a mere ...
Related articles »